Claims
- 1. A compound of the formula (I) in racemic, enantiomeric form or any combination of these forms, in which:R1 is selected from the group consisting of an amino (C2-C7)alkyl, aminoalkylarylalkyll, aminoalkylcycloalkylalkyl, (C1-C-15)alkyl, (C3-C7)cycloalkyl, (C1-C6)alkyl(C3-C6)cycloalkyl, (C3-C6)cycalkylalkyl, R2 represents an optionally substituted carbocyclic aryl consisting of a system of rings at least one of which is aromatic or R2 represents one of the radicals represented below: R3 represents a linear or branched alkyl radical containing 1 to 6 carbon atoms or R3 represents an optionally substituted carbocyclic aryl radical, said carbocyclic aryl radical consisting of a system of rings at least one of which is aromatic, or R3 is R4 is H or alkyl of 1 to 6 carbon atoms, i)for R2, when the group is substituted, it is substituted 1 to 5 times (apart from the bond which connects it to the rest of the molecule) by at least one member of the group consisting of halogen, alkyl of 1 to 6 atoms, linear or branched alkoxy containing 1 to 6 carbon atoms, linear or branched alkythio of 1 to 6 carbon atoms, haloalkyl of 1 to 6 carbon atoms alkenyl, haloalkoxy of 1 to 6 carbon atoms, nitro, cyano, azido, So2N, mono- or di-alkylamino the alkyl of which have 1 to 6 carbon atoms, aminoalkyl alkyl of which has 1 to 6 carbon atoms, aralkoxy of which the araloxy has 1 to 6 carbon atoms, or aryl, which two substituents can, if appropriate, be connected together and form a ring, ii) for R3, when aryl group(s) (originating from an aryl or aralkyl) is the carbocyclic aryl or aralkyl radicals have 1 to 5 substituents selected from the group consisting of a halogen, alkyl of 1 to 6 carbon atoms, hydroxy, alkoxy of 1 to 6 carbon atoms, haloalkyl of 1 to 6 carbon atoms, haloalkyl of 1 to 6 atoms, haloalkoxy of 1 to 6 carbon atoms, nitro, cyano, azido, mono or di-alkylamino the alkyls have 1 to 6 carbon atoms, pyrrolidinyl, morpholinyl, aralkoxy the alkoxy has 1 to 6 carbon atoms, or aryl, which two substituents can, if appropriate, be connected together and form a ring, or salt of a compound of formula (I).
- 2. Compound according to claim 1, characterized in that:R1 is of one of the following radicals: R2 represents one of the following radicals: R3 represents one of the following radicals R4 represents H, or a linear or branched alkyl radical containing 1 to 6 carbons atoms.
- 3. A compound of claim 1 having the formula in which: and R4 is H.
- 4. Process for the preparation of a compound of general formula (I)a R1 represents a —CH2—Al—NH2 radical, in which Al represents a —(CH2)n—, aralkylene or cycloalkylalkylene radical, n and p represent integers from 1 to 6; R2 and R4 represent the same radicals as in general formula (I) as defined in claim 1; and R3 represents the same radicals as in general formula (I) as defined in claim 1, said process being characterized in that it comprises the following successive stages: 1) treatment, in an aprotic solvent such as dichloromethane or dimethylformamide, of a p-nitrophenylcarbonate Wang resin with a large excess of R1—NH2 symmetrical diamine; 2) treatment, in an aprotic solvent such as dichloromethane or dimethylformamide, of the resin isolated after stage 1) with an aromatic isothioncyanate of formula R2—N═C═S in which the R2 radical has the same meaning as in general formula (I)a; 3) treatment in an aprotic solvent such as dioxane or dimethylformamide, of the resin obtained in stage 2) with the compound of general formula (III) in which the R3 and R4 radicals are identical to those which have been defined in general formula (I)a: 4) cleavage of the resin under acid conditions; 5) treatment under basic conditions of the product obtained after stage 4).
- 5. Process for the preparation of a compound of general formula (I)b in which:R1 represents the same radicals as in general formula (I) as defined in claim 1, with the exception of the —CH2—Al—NH2 type radicals, in which Al represents a —(CH2)n—, aralkylene or cycloalkylalkylene radical, n and p representing integers from 1 to 6, R2 represents an aminoalkylphenyl radical; R3 represents the same radicals as in general formula (I) as defined in claim 1, and R4 represents the same radicals as in general formula (I) as defined in claim 1; said process being characterized in that it comprises the following successive stages: 1) treatment, in an aprotic solvent such as dichloromethane or dimethylformamide, of a p-nitrophenylcarbonate Wang resin with an excess of aminoalkylaniline of formula R2—NH2 in which the R2 radical has the same meaning as in general formula (I)b; 2) treatment, in an aprotic solvent such as dichloromethane or dimethylformamide, if the resin isolated after stage 1) with an isothiocyanate of formula R1—N═C═S in which the R1 radical has the same meaning as in general formula (I)b; 3) treatment, in an aprotic solvent such as dioxane or dimethylformamide, of the resin obtained in stage 2) with the compound of general formula (III) in which the R3 and R4 radical are identical to those which have been defined in general formula (I)b; 4) cleavage of the resin under acid conditions; 6) treatment under basic conditions of the product obtained after stage 4.
- 6. A composition for treating pathological disorders are selected from the group consisting of acromegalia, hypophyseal adenomas, gastrointestinal bleeding and endocrinic gastroenteropancreatic tumors caused by somatostatin receptors comprising an amount of a compound of claim 1 sufficient to inactivate somatostatin receptors and a pharmaceutical carrier.
- 7. A method of treating pathological disorders are selected from the group consisting of acromegalia, hypophyseal adenomas, gastrointestinal bleeding and endocrinic gastroenteropancreatic tumors caused by somatostatin receptors in warm-blooded animals comprising administering to warm-blooded animals in need thereof an amount of a compound of claim 6 sufficient to inactivate somatostating receptors.
Priority Claims (1)
Number |
Date |
Country |
Kind |
99 09496 |
Jul 1999 |
FR |
|
Parent Case Info
This application is a 371 of PCT/FR00/02095 filed Jul. 21, 2000.
PCT Information
Filing Document |
Filing Date |
Country |
Kind |
PCT/FR00/02095 |
|
WO |
00 |
Publishing Document |
Publishing Date |
Country |
Kind |
WO01/07424 |
2/1/2001 |
WO |
A |
US Referenced Citations (1)
Number |
Name |
Date |
Kind |
4421757 |
Lang et al. |
Dec 1983 |
A |